Compare Charles River Laboratories Intl. Inc (CRL) vs Medtronic PLC (MDT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Medtronic PLC — how do they compare? Charles River Laboratories Intl. Inc trades at $301.79 (market cap $14.23B), while Medtronic PLC trades at $88.48 (market cap $112.24B). The key difference: Medtronic PLC is far larger — about 7.9× Charles River Laboratories Intl. Inc's market cap, and Medtronic PLC pays a 3.28% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Medtronic PLC for 63 Days on average.
| CRL | MDT | |
|---|---|---|
Market Cap | $14.23B | $112.24B |
Volume | 1,176,885 | 105,663,236 |
Sector | Health | Health |
52-Week High | $310.77 | $105.35 |
52-Week Low | $149.93 | $73.75 |
Typical Hold Time | 33 Days | 63 Days |
Enterprise Value | $17.06B | $131.58B |
Dividend Yield | — | 3.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $298.00, down 0.77% on the day, with a bullish technical signal supported by moving averages. The company has beaten earnings estimates for three consecutive quarters, though it reported a net loss of -$144.34M for 2025. Analyst consensus is strongly positive with a $305.50 price target, and recent news highlights a strategic growth plan targeting 5%-7% revenue growth by 2030.
The stock's outlook is supported by strong analyst buy ratings and a clear growth strategy, but faces risks from negative profitability metrics and high valuation multiples. Investment opportunity hinges on successful execution of margin expansion and cost savings initiatives, while key risks include persistent net losses and competitive pressures in the healthcare services sector.
Medtronic (MDT) trades at $87.75, up 2.62% today, with strong fundamental performance including three consecutive quarterly earnings beats and a 49-year dividend growth streak. The stock shows bearish technical signals but maintains solid profitability with 13.93% net margins and positive cash flow trends. Recent regulatory approvals for medical devices and raised guidance signal operational momentum despite mixed technical indicators.
Outlook remains positive with analyst consensus at $97.80 (11% upside) and no sell ratings, though technical weakness and increasing debt-to-asset ratios pose near-term risks. The 3.2% dividend yield provides income support while revenue growth acceleration to $37.5B projected for 2026 offers growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →
